CERE 110

Drug Profile

CERE 110

Alternative Names: AAV-NGF; CERE-110; NGF-AAV

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Sangamo BioSciences
  • Class Gene therapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 01 Apr 2015 Ceregene completes a phase II trial in Alzheimer's disease in USA (NCT00876863)
  • 01 Mar 2015 Discontinued - Phase-II for Alzheimer's disease in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top